Ustekinumab is indicated for the management of moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults and children 6 years or older who are candidates for phototherapy or systemic therapy. It is in a class of medications called monoclonal antibodies. Ustekinumab is used alone or in combination with methotrexate (rasuvo, otrexup, trexall) to treat psoriatic arthritis in adults. Psoriatic arthritis is a condition that causes joint pain and swelling and scales on the skin. Moreover, it is also used to treat Crohn's disease and ulcerative colitis. However, Crohn's disease is a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever. Ustekinumab works by stopping the action of certain cells in the body that cause the symptoms of psoriatic arthritis, plaque psoriasis, ulcerative colitis, and Crohn's disease. Common side effects include nausea, headache, tiredness runny, stuffed nose, or sneezing, and joint pain. Furthermore, other serious side effects include seizures, vision changes, difficulty in breathing, and others.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the ustekinumab market.

Top Impacting Factors

• Rise in prevalence of psoriasis patients across the globe drives the growth of the ustekinumab market.
• In addition, changes in lifestyles, increase in inclination toward alcohol consumption and smoking, unhealthy diets, and sedentary living are making people prone to this condition (psoriasis), which further influences the market growth.
• Furthermore, continuous economic development with developing healthcare infrastructure and improving healthcare awareness have been further supporting the market growth.
• On the contrary, rise in awareness about the prevention and treatment of psoriasis and increase in investments in R&D activities to develop novel treatment for psoriasis are expected to offer lucrative growth opportunities for the expansion of the market during the forecast period.
• However, adverse effects of ustekinumab such as seizures, vision changes, and difficulty in breathing is expected to hamper the growth of the market.

Market Trends

New Product Launches to Flourish the Market

In February 2019, Janssen Biotech Inc., a biotechnology company, received the United States Food and Drug Administration approved TREMFYA for the treatment of severe plaque psoriasis.

In July 2020, Fujifilm Kyowa Kirin Biologics received the Japanese regulatory approval for manufacturing and marketing of the first adalimumab biosimilar in the island country for the indication of psoriasis vulgaris, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis, entero-behcet's disease, and Crohn's disease.

In August 2020, Lupin Limited and Mylan launched the biosimilar etanercept Nepexto after receiving marketing authorization from the European Commission in May 2020 for indications, including psoriatic arthritis and plaque psoriasis.

Key Benefits of the Report

• This study presents the analytical depiction of the ustekinumab market industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
• The current market is quantitatively analyzed to highlight the market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Ustekinumab Market Report

• Which are the leading market players active in the ustekinumab market?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities of the market?
• What future projections would help in taking further strategic steps?
• What is ustekinumab market?
• What is ustekinumab market prediction in the future?
• Who are the leading global players in the ustekinumab market?
• What are the current trends and predicted trends?
• What are the key benefits of the ustekinumab market report?

 Key Market Segments

• By Dosage Form
  • Capsule
  • Tablets
• By Distribution Channel
  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

 
Key Market Players

• Stada
• NeuClone
• Formycon
• Alvotech
• Meiji
• Johnson and Johnson
• Fuji Pharma
• Mitsubishi Tanabe
• Outlook Therapeutics
• EPIRUS BioPharma

• CHAPTER 1: INTRODUCTION

  • 1.1. Report Description

  • 1.2. Key Market Segments

  • 1.3. Key Benefits

  • 1.4. Research Methodology

    • 1.4.1. Primary Research

    • 1.4.2. Secondary Research

    • 1.4.3. Analyst Tools and Models

• CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

• CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope

  • 3.2. Key Findings

    • 3.2.1. Top Investment Pockets

    • 3.2.2. Top Winning Strategies

  • 3.3. Porter's Five Forces Analysis

    • 3.3.1. Bargaining Power of Suppliers

    • 3.3.2. Threat of New Entrants

    • 3.3.3. Threat of Substitutes

    • 3.3.4. Competitive Rivalry

    • 3.3.5. Bargaining Power among Buyers

  • 3.5. Market Dynamics

    • 3.5.1. Drivers

    • 3.5.2. Restraints

    • 3.5.3. Opportunities

• CHAPTER 4: USTEKINUMAB MARKET, BY DOSAGE FORM

  • 4.1. Market Overview

    • 4.1.1 Market Size and Forecast, By Dosage Form

  • 4.2. Capsule

    • 4.2.1. Key Market Trends, Growth Factors and Opportunities

    • 4.2.2. Market Size and Forecast, By Region

    • 4.2.3. Market Share Analysis, By Country

  • 4.3. Tablets

    • 4.3.1. Key Market Trends, Growth Factors and Opportunities

    • 4.3.2. Market Size and Forecast, By Region

    • 4.3.3. Market Share Analysis, By Country

• CHAPTER 5: USTEKINUMAB MARKET, BY DISTRIBUTION CHANNEL

  • 5.1. Market Overview

    • 5.1.1 Market Size and Forecast, By Distribution Channel

  • 5.2. Hospitals

    • 5.2.1. Key Market Trends, Growth Factors and Opportunities

    • 5.2.2. Market Size and Forecast, By Region

    • 5.2.3. Market Share Analysis, By Country

  • 5.3. Clinics

    • 5.3.1. Key Market Trends, Growth Factors and Opportunities

    • 5.3.2. Market Size and Forecast, By Region

    • 5.3.3. Market Share Analysis, By Country

  • 5.4. Retail Pharmacies

    • 5.4.1. Key Market Trends, Growth Factors and Opportunities

    • 5.4.2. Market Size and Forecast, By Region

    • 5.4.3. Market Share Analysis, By Country

  • 5.5. Online Pharmacies

    • 5.5.1. Key Market Trends, Growth Factors and Opportunities

    • 5.5.2. Market Size and Forecast, By Region

    • 5.5.3. Market Share Analysis, By Country

• CHAPTER 6: USTEKINUMAB MARKET, BY REGION

  • 6.1. Market Overview

    • 6.1.1 Market Size and Forecast, By Region

  • 6.2. North America

    • 6.2.1. Key Market Trends and Opportunities

    • 6.2.2. Market Size and Forecast, By Dosage Form

    • 6.2.3. Market Size and Forecast, By Distribution Channel

    • 6.2.4. Market Size and Forecast, By Country

    • 6.2.5. U.S. Ustekinumab Market

      • 6.2.5.1. Market Size and Forecast, By Dosage Form

      • 6.2.5.2. Market Size and Forecast, By Distribution Channel

    • 6.2.6. Canada Ustekinumab Market

      • 6.2.6.1. Market Size and Forecast, By Dosage Form

      • 6.2.6.2. Market Size and Forecast, By Distribution Channel

    • 6.2.7. Mexico Ustekinumab Market

      • 6.2.7.1. Market Size and Forecast, By Dosage Form

      • 6.2.7.2. Market Size and Forecast, By Distribution Channel

  • 6.3. Europe

    • 6.3.1. Key Market Trends and Opportunities

    • 6.3.2. Market Size and Forecast, By Dosage Form

    • 6.3.3. Market Size and Forecast, By Distribution Channel

    • 6.3.4. Market Size and Forecast, By Country

    • 6.3.5. France Ustekinumab Market

      • 6.3.5.1. Market Size and Forecast, By Dosage Form

      • 6.3.5.2. Market Size and Forecast, By Distribution Channel

    • 6.3.6. Germany Ustekinumab Market

      • 6.3.6.1. Market Size and Forecast, By Dosage Form

      • 6.3.6.2. Market Size and Forecast, By Distribution Channel

    • 6.3.7. Italy Ustekinumab Market

      • 6.3.7.1. Market Size and Forecast, By Dosage Form

      • 6.3.7.2. Market Size and Forecast, By Distribution Channel

    • 6.3.8. Spain Ustekinumab Market

      • 6.3.8.1. Market Size and Forecast, By Dosage Form

      • 6.3.8.2. Market Size and Forecast, By Distribution Channel

    • 6.3.9. UK Ustekinumab Market

      • 6.3.9.1. Market Size and Forecast, By Dosage Form

      • 6.3.9.2. Market Size and Forecast, By Distribution Channel

    • 6.3.10. Russia Ustekinumab Market

      • 6.3.10.1. Market Size and Forecast, By Dosage Form

      • 6.3.10.2. Market Size and Forecast, By Distribution Channel

    • 6.3.11. Rest Of Europe Ustekinumab Market

      • 6.3.11.1. Market Size and Forecast, By Dosage Form

      • 6.3.11.2. Market Size and Forecast, By Distribution Channel

  • 6.4. Asia-Pacific

    • 6.4.1. Key Market Trends and Opportunities

    • 6.4.2. Market Size and Forecast, By Dosage Form

    • 6.4.3. Market Size and Forecast, By Distribution Channel

    • 6.4.4. Market Size and Forecast, By Country

    • 6.4.5. China Ustekinumab Market

      • 6.4.5.1. Market Size and Forecast, By Dosage Form

      • 6.4.5.2. Market Size and Forecast, By Distribution Channel

    • 6.4.6. Japan Ustekinumab Market

      • 6.4.6.1. Market Size and Forecast, By Dosage Form

      • 6.4.6.2. Market Size and Forecast, By Distribution Channel

    • 6.4.7. India Ustekinumab Market

      • 6.4.7.1. Market Size and Forecast, By Dosage Form

      • 6.4.7.2. Market Size and Forecast, By Distribution Channel

    • 6.4.8. South Korea Ustekinumab Market

      • 6.4.8.1. Market Size and Forecast, By Dosage Form

      • 6.4.8.2. Market Size and Forecast, By Distribution Channel

    • 6.4.9. Australia Ustekinumab Market

      • 6.4.9.1. Market Size and Forecast, By Dosage Form

      • 6.4.9.2. Market Size and Forecast, By Distribution Channel

    • 6.4.10. Thailand Ustekinumab Market

      • 6.4.10.1. Market Size and Forecast, By Dosage Form

      • 6.4.10.2. Market Size and Forecast, By Distribution Channel

    • 6.4.11. Malaysia Ustekinumab Market

      • 6.4.11.1. Market Size and Forecast, By Dosage Form

      • 6.4.11.2. Market Size and Forecast, By Distribution Channel

    • 6.4.12. Indonesia Ustekinumab Market

      • 6.4.12.1. Market Size and Forecast, By Dosage Form

      • 6.4.12.2. Market Size and Forecast, By Distribution Channel

    • 6.4.13. Rest of Asia Pacific Ustekinumab Market

      • 6.4.13.1. Market Size and Forecast, By Dosage Form

      • 6.4.13.2. Market Size and Forecast, By Distribution Channel

  • 6.5. LAMEA

    • 6.5.1. Key Market Trends and Opportunities

    • 6.5.2. Market Size and Forecast, By Dosage Form

    • 6.5.3. Market Size and Forecast, By Distribution Channel

    • 6.5.4. Market Size and Forecast, By Country

    • 6.5.5. Brazil Ustekinumab Market

      • 6.5.5.1. Market Size and Forecast, By Dosage Form

      • 6.5.5.2. Market Size and Forecast, By Distribution Channel

    • 6.5.6. South Africa Ustekinumab Market

      • 6.5.6.1. Market Size and Forecast, By Dosage Form

      • 6.5.6.2. Market Size and Forecast, By Distribution Channel

    • 6.5.7. Saudi Arabia Ustekinumab Market

      • 6.5.7.1. Market Size and Forecast, By Dosage Form

      • 6.5.7.2. Market Size and Forecast, By Distribution Channel

    • 6.5.8. UAE Ustekinumab Market

      • 6.5.8.1. Market Size and Forecast, By Dosage Form

      • 6.5.8.2. Market Size and Forecast, By Distribution Channel

    • 6.5.9. Argentina Ustekinumab Market

      • 6.5.9.1. Market Size and Forecast, By Dosage Form

      • 6.5.9.2. Market Size and Forecast, By Distribution Channel

    • 6.5.10. Rest of LAMEA Ustekinumab Market

      • 6.5.10.1. Market Size and Forecast, By Dosage Form

      • 6.5.10.2. Market Size and Forecast, By Distribution Channel

• CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction

  • 7.2. Top Winning Strategies

  • 7.3. Product Mapping Of Top 10 Player

  • 7.4. Competitive Dashboard

  • 7.5. Competitive Heatmap

  • 7.6. Top Player Positioning, 2024

• CHAPTER 8: COMPANY PROFILES

  • 8.1. Meiji

    • 8.1.1. Company Overview

    • 8.1.2. Key Executives

    • 8.1.3. Company Snapshot

    • 8.1.4. Operating Business Segments

    • 8.1.5. Product Portfolio

    • 8.1.6. Business Performance

    • 8.1.7. Key Strategic Moves and Developments

  • 8.2. Johnson And Johnson

    • 8.2.1. Company Overview

    • 8.2.2. Key Executives

    • 8.2.3. Company Snapshot

    • 8.2.4. Operating Business Segments

    • 8.2.5. Product Portfolio

    • 8.2.6. Business Performance

    • 8.2.7. Key Strategic Moves and Developments

  • 8.3. Alvotech

    • 8.3.1. Company Overview

    • 8.3.2. Key Executives

    • 8.3.3. Company Snapshot

    • 8.3.4. Operating Business Segments

    • 8.3.5. Product Portfolio

    • 8.3.6. Business Performance

    • 8.3.7. Key Strategic Moves and Developments

  • 8.4. Fuji Pharma

    • 8.4.1. Company Overview

    • 8.4.2. Key Executives

    • 8.4.3. Company Snapshot

    • 8.4.4. Operating Business Segments

    • 8.4.5. Product Portfolio

    • 8.4.6. Business Performance

    • 8.4.7. Key Strategic Moves and Developments

  • 8.5. Mitsubishi Tanabe

    • 8.5.1. Company Overview

    • 8.5.2. Key Executives

    • 8.5.3. Company Snapshot

    • 8.5.4. Operating Business Segments

    • 8.5.5. Product Portfolio

    • 8.5.6. Business Performance

    • 8.5.7. Key Strategic Moves and Developments

  • 8.6. Stada

    • 8.6.1. Company Overview

    • 8.6.2. Key Executives

    • 8.6.3. Company Snapshot

    • 8.6.4. Operating Business Segments

    • 8.6.5. Product Portfolio

    • 8.6.6. Business Performance

    • 8.6.7. Key Strategic Moves and Developments

  • 8.7. EPIRUS BioPharma

    • 8.7.1. Company Overview

    • 8.7.2. Key Executives

    • 8.7.3. Company Snapshot

    • 8.7.4. Operating Business Segments

    • 8.7.5. Product Portfolio

    • 8.7.6. Business Performance

    • 8.7.7. Key Strategic Moves and Developments

  • 8.8. Formycon

    • 8.8.1. Company Overview

    • 8.8.2. Key Executives

    • 8.8.3. Company Snapshot

    • 8.8.4. Operating Business Segments

    • 8.8.5. Product Portfolio

    • 8.8.6. Business Performance

    • 8.8.7. Key Strategic Moves and Developments

  • 8.9. NeuClone

    • 8.9.1. Company Overview

    • 8.9.2. Key Executives

    • 8.9.3. Company Snapshot

    • 8.9.4. Operating Business Segments

    • 8.9.5. Product Portfolio

    • 8.9.6. Business Performance

    • 8.9.7. Key Strategic Moves and Developments

  • 8.10. Outlook Therapeutics

    • 8.10.1. Company Overview

    • 8.10.2. Key Executives

    • 8.10.3. Company Snapshot

    • 8.10.4. Operating Business Segments

    • 8.10.5. Product Portfolio

    • 8.10.6. Business Performance

    • 8.10.7. Key Strategic Moves and Developments

• LIST OF TABLES

• TABLE 1. GLOBAL USTEKINUMAB MARKET, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 2. GLOBAL USTEKINUMAB MARKET FOR CAPSULE, BY REGION, 2025-2033 ($MILLION)
• TABLE 3. GLOBAL USTEKINUMAB MARKET FOR TABLETS, BY REGION, 2025-2033 ($MILLION)
• TABLE 4. GLOBAL USTEKINUMAB MARKET, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 5. GLOBAL USTEKINUMAB MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
• TABLE 6. GLOBAL USTEKINUMAB MARKET FOR CLINICS, BY REGION, 2025-2033 ($MILLION)
• TABLE 7. GLOBAL USTEKINUMAB MARKET FOR RETAIL PHARMACIES, BY REGION, 2025-2033 ($MILLION)
• TABLE 8. GLOBAL USTEKINUMAB MARKET FOR ONLINE PHARMACIES, BY REGION, 2025-2033 ($MILLION)
• TABLE 9. GLOBAL USTEKINUMAB MARKET, BY REGION, 2025-2033 ($MILLION)
• TABLE 10. NORTH AMERICA USTEKINUMAB, BY REGION, 2025-2033 ($MILLION)
• TABLE 11. NORTH AMERICA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 12. NORTH AMERICA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 13. U.S. USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 14. U.S. USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 15. CANADA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 16. CANADA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 17. MEXICO USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 18. MEXICO USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 19. EUROPE USTEKINUMAB, BY REGION, 2025-2033 ($MILLION)
• TABLE 20. EUROPE USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 21. EUROPE USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 22. FRANCE USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 23. FRANCE USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 24. GERMANY USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 25. GERMANY USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 26. ITALY USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 27. ITALY USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 28. SPAIN USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 29. SPAIN USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 30. UK USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 31. UK USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 32. RUSSIA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 33. RUSSIA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 34. REST OF EUROPE USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 35. REST OF EUROPE USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 36. ASIA-PACIFIC USTEKINUMAB, BY REGION, 2025-2033 ($MILLION)
• TABLE 37. ASIA-PACIFIC USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 38. ASIA-PACIFIC USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 39. CHINA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 40. CHINA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 41. JAPAN USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 42. JAPAN USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 43. INDIA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 44. INDIA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 45. SOUTH KOREA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 46. SOUTH KOREA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 47. AUSTRALIA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 48. AUSTRALIA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 49. THAILAND USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 50. THAILAND USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 51. MALAYSIA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 52. MALAYSIA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 53. INDONESIA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 54. INDONESIA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 55. REST OF ASIA PACIFIC USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 56. REST OF ASIA PACIFIC USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 57. LAMEA USTEKINUMAB, BY REGION, 2025-2033 ($MILLION)
• TABLE 58. LAMEA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 59. LAMEA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 60. BRAZIL USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 61. BRAZIL USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 62. SOUTH AFRICA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 63. SOUTH AFRICA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 64. SAUDI ARABIA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 65. SAUDI ARABIA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 66. UAE USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 67. UAE USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 68. ARGENTINA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 69. ARGENTINA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 70. REST OF LAMEA USTEKINUMAB, BY DOSAGE FORM, 2025-2033 ($MILLION)
• TABLE 71. REST OF LAMEA USTEKINUMAB, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
• TABLE 72. MEIJI: KEY EXECUTIVES
• TABLE 73. MEIJI: COMPANY SNAPSHOT
• TABLE 74. MEIJI: OPERATING SEGMENTS
• TABLE 75. MEIJI: PRODUCT PORTFOLIO
• TABLE 76. MEIJI: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 77. JOHNSON AND JOHNSON: KEY EXECUTIVES
• TABLE 78. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
• TABLE 79. JOHNSON AND JOHNSON: OPERATING SEGMENTS
• TABLE 80. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
• TABLE 81. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 82. ALVOTECH: KEY EXECUTIVES
• TABLE 83. ALVOTECH: COMPANY SNAPSHOT
• TABLE 84. ALVOTECH: OPERATING SEGMENTS
• TABLE 85. ALVOTECH: PRODUCT PORTFOLIO
• TABLE 86. ALVOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 87. FUJI PHARMA: KEY EXECUTIVES
• TABLE 88. FUJI PHARMA: COMPANY SNAPSHOT
• TABLE 89. FUJI PHARMA: OPERATING SEGMENTS
• TABLE 90. FUJI PHARMA: PRODUCT PORTFOLIO
• TABLE 91. FUJI PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 92. MITSUBISHI TANABE: KEY EXECUTIVES
• TABLE 93. MITSUBISHI TANABE: COMPANY SNAPSHOT
• TABLE 94. MITSUBISHI TANABE: OPERATING SEGMENTS
• TABLE 95. MITSUBISHI TANABE: PRODUCT PORTFOLIO
• TABLE 96. MITSUBISHI TANABE: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 97. STADA: KEY EXECUTIVES
• TABLE 98. STADA: COMPANY SNAPSHOT
• TABLE 99. STADA: OPERATING SEGMENTS
• TABLE 100. STADA: PRODUCT PORTFOLIO
• TABLE 101. STADA: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 102. EPIRUS BIOPHARMA: KEY EXECUTIVES
• TABLE 103. EPIRUS BIOPHARMA: COMPANY SNAPSHOT
• TABLE 104. EPIRUS BIOPHARMA: OPERATING SEGMENTS
• TABLE 105. EPIRUS BIOPHARMA: PRODUCT PORTFOLIO
• TABLE 106. EPIRUS BIOPHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 107. FORMYCON: KEY EXECUTIVES
• TABLE 108. FORMYCON: COMPANY SNAPSHOT
• TABLE 109. FORMYCON: OPERATING SEGMENTS
• TABLE 110. FORMYCON: PRODUCT PORTFOLIO
• TABLE 111. FORMYCON: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 112. NEUCLONE: KEY EXECUTIVES
• TABLE 113. NEUCLONE: COMPANY SNAPSHOT
• TABLE 114. NEUCLONE: OPERATING SEGMENTS
• TABLE 115. NEUCLONE: PRODUCT PORTFOLIO
• TABLE 116. NEUCLONE: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 117. OUTLOOK THERAPEUTICS: KEY EXECUTIVES
• TABLE 118. OUTLOOK THERAPEUTICS: COMPANY SNAPSHOT
• TABLE 119. OUTLOOK THERAPEUTICS: OPERATING SEGMENTS
• TABLE 120. OUTLOOK THERAPEUTICS: PRODUCT PORTFOLIO
• TABLE 121. OUTLOOK THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS

• LIST OF FIGURES

• FIGURE 1. GLOBAL USTEKINUMAB MARKET SEGMENTATION
• FIGURE 2. GLOBAL USTEKINUMAB MARKET
• FIGURE 3. SEGMENTATION USTEKINUMAB MARKET
• FIGURE 4. TOP INVESTMENT POCKET IN USTEKINUMAB MARKET
• FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
• FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
• FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
• FIGURE 8. LOW THREAT OF SUBSTITUTION
• FIGURE 9. HIGH COMPETITIVE RIVALRY
• FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALUSTEKINUMAB MARKET
• FIGURE 11. USTEKINUMAB MARKET SEGMENTATION, BY BY DOSAGE FORM
• FIGURE 12. USTEKINUMAB MARKET FOR CAPSULE, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 13. USTEKINUMAB MARKET FOR TABLETS, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 14. USTEKINUMAB MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
• FIGURE 15. USTEKINUMAB MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 16. USTEKINUMAB MARKET FOR CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 17. USTEKINUMAB MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 18. USTEKINUMAB MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
• FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
• FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
• FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 23. COMPETITIVE DASHBOARD
• FIGURE 24. COMPETITIVE HEATMAP: USTEKINUMAB MARKET
• FIGURE 25. TOP PLAYER POSITIONING, 2024
• FIGURE 26. MEIJI: NET SALES, 2022-2024 ($MILLION)
• FIGURE 27. MEIJI: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 28. MEIJI: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 29. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
• FIGURE 30. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 31. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 32. ALVOTECH: NET SALES, 2022-2024 ($MILLION)
• FIGURE 33. ALVOTECH: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 34. ALVOTECH: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 35. FUJI PHARMA: NET SALES, 2022-2024 ($MILLION)
• FIGURE 36. FUJI PHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 37. FUJI PHARMA: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 38. MITSUBISHI TANABE: NET SALES, 2022-2024 ($MILLION)
• FIGURE 39. MITSUBISHI TANABE: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 40. MITSUBISHI TANABE: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 41. STADA: NET SALES, 2022-2024 ($MILLION)
• FIGURE 42. STADA: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 43. STADA: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 44. EPIRUS BIOPHARMA: NET SALES, 2022-2024 ($MILLION)
• FIGURE 45. EPIRUS BIOPHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 46. EPIRUS BIOPHARMA: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 47. FORMYCON: NET SALES, 2022-2024 ($MILLION)
• FIGURE 48. FORMYCON: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 49. FORMYCON: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 50. NEUCLONE: NET SALES, 2022-2024 ($MILLION)
• FIGURE 51. NEUCLONE: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 52. NEUCLONE: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 53. OUTLOOK THERAPEUTICS: NET SALES, 2022-2024 ($MILLION)
• FIGURE 54. OUTLOOK THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 55. OUTLOOK THERAPEUTICS: REVENUE SHARE, BY REGION, 2024 (%)